AbCellera Biologics Inc (NASDAQ:ABCL) has a beta value of 0.44 and has seen 0.67 million shares traded in the recent trading session. The company, currently valued at $997.18M, closed the recent trade at $3.39 per share which meant it lost -$0.12 on the day or -3.38% during that session. The ABCL stock price is -137.46% off its 52-week high price of $8.05 and -3.54% below the 52-week low of $3.51. The 3-month trading volume is 1.27 million shares.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Sporting -3.38% in the red today, the stock has traded in the red over the last five days, when the ABCL stock price touched $3.39 or saw a rise of 12.63%. Year-to-date, AbCellera Biologics Inc shares have moved -40.61%, while the 5-day performance has seen it change -10.29%. Over the past 30 days, the shares of AbCellera Biologics Inc (NASDAQ:ABCL) have changed -11.46%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AbCellera Biologics Inc (ABCL) estimates and forecasts
Figures show that AbCellera Biologics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -30.37% over the past 6 months, with this year growth rate of -17.65%, compared to 15.40% for the industry. Revenue growth from the last financial year stood is estimated to be 9.10%.
8 analysts offering their estimates for the company have set an average revenue estimate of 10.15M for the current quarter. 8 have an estimated revenue figure of 10.89M for the next ending quarter. Year-ago sales stood 10.06M and 11.84M respectively for this quarter and the next, and analysts expect sales will grow by 0.90% for the current quarter and 9.10% for the next.
Earnings growth for 2024 is a modest 6.32% while over the next 5 years, the company’s earnings are expected to increase by 10.00%.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
